RE:RE:Do the math…Good conservative stab at it REV !!!
Lets do a bunch of worst case assumptions to see how you might get there:
- No Sales in Canada (fair if it was FDA approved?)
- $ 2B USD addressable market (really s/b MUCH higher with Canada included, 3 filter uses in some cases as supported by some studies, use of PMX for other conditions besides ESS e.g. cardiomyopathy, etc.)
- 140,000 cases & only $ 6750/filter (could be much higher with great results i.e. higher ARR, and EDEN study supporting expanded use)
- zero world-wide EAA sales (how realistic is zero EAA sales in every other country, once FDA slaps the gold standard on PMX which requires a companion diagnostic?...or even as a triage tool to detect ESS in the first place?, etc.)
- ONLY 35% market penetration (on a new SOC? ultra conservative as DOC's would have to use to try to save lives in teh ICU wouldn't they?)
- 400 million shares (allowing for more & future dilution)
- 3 X P/S ratio (low end of the scale per industry standards with the average more like 7.75)
- 1.35 FX exchange rate.
= $ 7.00 CAD
Don't do the calcs with a 7.75 PS ratio and more realistic revenue assumptions. You'll drive yourself crazy. lol
MM